SERPINA1 and cystic fibrosis: In our cohort population, 12 (6.9%) of CF patients should be genetically tested according to AAT serum level less or equal to 110 mg/dL: 2 (22.2%) in the S-allele heterozygosity group and 10 (6.1%) in the wild-type group (p = 0.065).